Navigation Links
St. Jude defines eye cancer gene's role in retinal development
Date:1/16/2008

A genetic discovery led by scientists at St. Jude Childrens Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.

A series of complex developmental processes must be carefully orchestrated for the eye to form correctly, said Michael Dyer, Ph.D., associate member in the St. Jude Department of Developmental Neurobiology. One important aspect of this coordination is that retinal thickness be the same, irrespective of eye size. For example, the mouse eye is about 5,000 times smaller than that of the elephant eye, but the retinal thickness in these two species is comparable.

Working with mice, the researchers found that a gene called N-myc coordinates the growth of the retina and other eye structures to ensure the retina has the proper thickness necessary to convert light from the lens into nerve impulses that the brain transforms into images. Until their study, reported in the Jan. 15 issue of Genes & Development, almost nothing was known about the molecular mechanisms responsible for properly sizing the retina. Dyer is the papers senior author.

This represents the first example of a role for a Myc gene in retinal development, Dyer said. On the basis of our data, we propose that N-myc plays a central role in coordinating retinal proliferation with eye growth during development.

Genes in the Myc family carry out vital roles during prenatal development by regulating the proliferation, size, differentiation and survival of cells. Myc genes are also proto-oncogenesgenes in which a mutation enables them to transform normal cells into cancerous ones. Malfunctioning N-myc genes are often associated with pediatric neural cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

Recently, Dyer and his team identified the specific type of cell that gives rise to retinoblastoma, a potentially fatal malignant tumor in the retina that affects about 300 children in the United States annually. The determination of N-myc target genes during retinal development may also contribute to the current understanding of retinoblastoma progression, he said.

In the course of their study, the researchers discovered that N-myc is not involved in regulating cell survival or neuronal differentiation in the developing retina. However, the gene is crucial for the proper proliferation of retinal cells. In mice in which the scientists inactivated N-myc, the volume of the retina was significantly smaller than in mice with normally functioning N-myc.

The team found no evidence of an increase in progenitor cell deaths between normal and N-myc-deficient retinas. The investigators then concluded the smaller retinas likely resulted from an N-myc-related proliferation defect in the progenitor retinal cells.

The researchers hypothesize that N-mycs activity occurs early in the cascade of reactions that control development of the retina and other eye components. Therefore, when something inactivates the gene, the result is both a reduction in retinal progenitor cell proliferation and a reduction in the signaling cues that coordinate the growth of the eye and retina.

Importantly, for retinas to maintain nearly constant thickness across species that have different sizes of eyes, the total number of retinal cells must change several-fold, Dyer said. The identification of N-myc as a key regulator of these processes allows us to begin to understand the coordination of complex developmental programs in the developing eye and how these processes have evolved.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-495-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related biology news :

1. Genome update defines landscape of breast and colon cancers
2. New book defines promising young field of adult neurogenesis
3. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. ESF EURYI award winner aims to stop cancer cells reading their own DNA
6. Protein chatter linked to cancer activation
7. Newly created cancer stem cells could aid breast cancer research
8. Western diet linked to increased risk of colon cancer recurrence
9. Obesity and lack of exercise could enhance the risk of pancreatic cancer
10. Low levels of key protein may indicate pancreatic cancer risk
11. Birth records hold pancreatic cancer clue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
(Date:2/2/2017)... YORK , Feb. 2, 2017  EyeLock LLC, ... released a new white paper " What You Should ... The problem of ensuring user authenticity is a growing ... the authentication of users. However, traditional authentication schemes such ... Biometric authentication offers an elegant solution ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... -- Four US Biotech equities have been ... are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), Arrowhead Pharmaceuticals Inc. ... and Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ). ... are growing more bullish on the sector as a ... cash held overseas for tax reason by large US ...
(Date:2/27/2017)... ... ... The Catalyst Midwest premix manufacturing facility has been certified as organic, ... label organic services. , The first organic product is Organic 18 Percent Layer Feed, ... Marketing, which owns the facility. , Catalyst already has received the Safe Feed/Safe ...
(Date:2/24/2017)... SAN FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... awarding of a $224K grant from the National Institute of Mental Health (NIMH) for ... is based on Delpor’s PROZOR technology and is expected to deliver therapeutic ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
Breaking Biology Technology: